David H. Vesole

1990–2024 年に発表

104
論文数
26,353
被引用数
77
h 指数
102
i10 指数

被引用数

David H. Vesole の年別被引用数1948 年: 被引用 3 件1989 年: 被引用 1 件1990 年: 被引用 1 件1991 年: 被引用 4 件1992 年: 被引用 6 件1993 年: 被引用 8 件1994 年: 被引用 8 件1995 年: 被引用 13 件1996 年: 被引用 26 件1997 年: 被引用 27 件1998 年: 被引用 29 件1999 年: 被引用 40 件2000 年: 被引用 65 件2001 年: 被引用 60 件2002 年: 被引用 75 件2003 年: 被引用 114 件2004 年: 被引用 84 件2005 年: 被引用 110 件2006 年: 被引用 136 件2007 年: 被引用 205 件2008 年: 被引用 242 件2009 年: 被引用 247 件2010 年: 被引用 212 件2011 年: 被引用 278 件2012 年: 被引用 223 件2013 年: 被引用 248 件2014 年: 被引用 283 件2015 年: 被引用 236 件2016 年: 被引用 226 件2017 年: 被引用 182 件2018 年: 被引用 171 件2019 年: 被引用 589 件2020 年: 被引用 599 件2021 年: 被引用 588 件2022 年: 被引用 446 件2023 年: 被引用 249 件2024 年: 被引用 423 件2025 年: 被引用 182 件2026 年: 被引用 3 件1949〜1988 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,493 件、この内訳の 27.4%イタリア: 引用元論文 557 件、この内訳の 6.1%フランス: 引用元論文 552 件、この内訳の 6.1%ドイツ: 引用元論文 532 件、この内訳の 5.8%イギリス: 引用元論文 502 件、この内訳の 5.5%スペイン: 引用元論文 467 件、この内訳の 5.1%中国: 引用元論文 359 件、この内訳の 3.9%オランダ: 引用元論文 341 件、この内訳の 3.8%カナダ: 引用元論文 305 件、この内訳の 3.4%ギリシャ: 引用元論文 278 件、この内訳の 3.1%オーストラリア: 引用元論文 240 件、この内訳の 2.6%ベルギー: 引用元論文 224 件、この内訳の 2.5%
0%27.4%その他 24.7%

分野

  • Medicine82.6%
  • Immunology and Microbiology8.1%
  • Biochemistry, Genetics and Molecular Biology7.6%
  • Engineering0.4%
  • Mathematics0.2%
  • Neuroscience0.2%
  • その他0.9%

トピック

  • Multiple Myeloma Research and Treatments19.4%
  • Protein Degradation and Inhibitors7.9%
  • Peptidase Inhibition and Analysis4.2%
  • Cancer Treatment and Pharmacology3.6%
  • Hematopoietic Stem Cell Transplantation3.1%
  • CAR-T cell therapy research2.7%
  • その他59.1%

共著者

全論文

検索で開く
  1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

    著者: , , , , , , , , , , , , , , , , , , , , , - Blood 2011 被引用: 1,034

  2. International uniform response criteria for multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , on behalf of the International Myeloma Working Group - Leukemia 2006 被引用: 2,639

  3. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2010 被引用: 876

  4. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Katja Weisel, Rachid Baz, Vânia Hungria, Jesús G. Berdeja, Fernando Leal da Costa, Ângelo Maiolino, Anders Waage, David H. Vesole, Enrique M. Ocio, Hang Quach, Christoph Driessen, Joan Bladé, Xavier Leleu, Eloísa Riva, P. Leif Bergsagel, Jian Hou, Wee Joo Chng, Ulf‐Henrik Mellqvist, Dominik Dytfeld, Jean‐Luc Harousseau, Hartmut Goldschmidt, Jacob P. Laubach, Nikhil C. Munshi, Francesca Gay, Meral Beksaç, Luciano J. Costa, Martin Kaiser, Parameswaran Hari, Mario Boccadoro, Saad Z. Usmani, Sonja Zweegman, Sarah A. Holstein, Orhan Sezer, Simon J. Harrison, Hareth Nahi, Gordon Cook, María‐Victoria Mateos, S. Vincent Rajkumar, Meletios Α. Dimopoulos, Paul G. Richardson - The Lancet Oncology 2021 被引用: 268

  5. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2017 被引用: 520

  6. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline

    著者: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 被引用: 333

  7. Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld, Saad Z. Usmani, Karin Vanderkerken, David H. Vesole, Anders Waage, Sonja Zweegman, Paul G. Richardson, Joan Bladé - British Journal of Haematology 2021 被引用: 174

  8. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.

    著者: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 42

  9. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    著者: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 被引用: 419

  10. Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease

    著者: , , , , , , , , , , , , - New England Journal of Medicine 2007 被引用: 1,336

  11. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

    著者: , , , , , , , , , - The Lancet Oncology 2009 被引用: 933

  12. Bortezomib enhances dendritic cell (DC)–mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications

    著者: , , , , , - Blood 2007 被引用: 378

  13. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Blood 2014 被引用: 384

  14. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rafaël Fonseca, Giampaolo Merlini, Juan José Lahuerta, Joan Bladé, Robert Z. Orlowski, Jatin J. Shah, on behalf of the International Myeloma Working Group - Leukemia 2012 被引用: 383

  15. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 被引用: 259

  16. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mario Boccadoro, Brian G.M. Durie, Pieter Sonneveld, M. A. Hussein, on behalf of the International Myeloma Working Group - Leukemia 2007 被引用: 839

  17. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial

    著者: , , , , , , , , , , - Bone Marrow Transplantation 2003 被引用: 248

  18. Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)

    著者: , , , , , , , , , , , , , , , , , , , , , , - Blood Cancer Journal 2022 被引用: 40

  19. Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM).

    著者: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 102

  20. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , - Blood 2012 被引用: 434

  21. Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma

    著者: , , - Cancers 2021 被引用: 27

  22. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2009 被引用: 233

  23. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report

    著者: , , , , , , , , , , , , , , , , , , , , , - Cancer 2017 被引用: 87

  24. Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Leona Holmberg, Aimaz Afrough, Melhem Solh, Pashna N. Munshi, Taiga Nishihori, Larry D. Anderson, Baldeep Wirk, Gurbakhash Kaur, Muzaffar H. Qazilbash, Nina Shah, Shaji Kumar, Saad Z. Usmani - Blood Advances 2023 被引用: 36